{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:48:34Z","timestamp":1791838114188,"version":"4.3.4"},"reference-count":196,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eururo.2026.06.009","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:58:38Z","timestamp":1783108718000},"page":"347-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics"],"prefix":"10.1016","volume":"90","author":[{"given":"Stefano","family":"Fanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-7888","authenticated-orcid":false,"given":"Fabio","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Salfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliano J.","family":"Cerci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Gafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Hugosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Iagaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeru","family":"Kasivisvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dow-Mu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Lecouvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Naoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar R.","family":"Padhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Palapattu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Paone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Petralia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique J.","family":"Roobol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler M.","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Tempany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.Alberto","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula M.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelius","family":"Omlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.06.009_b0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0010","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2026.06.009_b0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of patients with advanced prostate cancer. Part I: intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management of patients with advanced prostate cancer: report from the advanced prostate cancer consensus conference 2021","volume":"82","author":"Gillessen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0025","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0030","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J Clinicians"},{"key":"10.1016\/j.eururo.2026.06.009_b0040","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0045","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0050","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2024.4011","article-title":"Prostate-specific antigen screening and 15-year prostate cancer mortality: a secondary analysis of the CAP randomized clinical trial","volume":"331","author":"Martin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.06.009_b0055","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European study of prostate cancer screening - 23-year follow-up","volume":"393","author":"Roobol","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0060","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bju.14580","article-title":"Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial","volume":"123","author":"Pinsky","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.06.009_b0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/jnci\/djr500","article-title":"Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up","volume":"104","author":"Andriole","year":"2012","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2026.06.009_b0070","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 years of Followup in the G\u00f6teborg Randomized Population-Based Prostate Cancer Screening Trial","volume":"208","author":"Fr\u00e5nlund","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.annonc.2025.12.009","article-title":"Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"37","author":"Walz","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0095","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2026.06.009_b0105","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.juro.2014.10.121","article-title":"The prostate health index selectively identifies clinically significant prostate cancer","volume":"193","author":"Loeb","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0110","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer","volume":"68","author":"Parekh","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0115","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0120","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","article-title":"Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score","volume":"70","author":"Van Neste","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0125","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jamaoncol.2016.0097","article-title":"A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy","volume":"2","author":"McKiernan","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0130","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.3390\/ijms26167667","article-title":"Biomarkers in localized prostate cancer: from diagnosis to treatment","volume":"26","author":"Lopez-Valcarcel","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eururo.2026.06.009_b0135","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0140","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the Impact study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0145","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ijc.11466","article-title":"Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis","volume":"107","author":"Watkins Bruner","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2026.06.009_b0150","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.juro.2014.09.018","article-title":"Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculator","volume":"193","author":"Grill","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0155","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.urology.2006.02.026","article-title":"Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial","volume":"68","author":"Pinsky","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.06.009_b0160","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.euo.2023.09.008","article-title":"Digital rectal examination is not a useful screening test for prostate cancer","volume":"6","author":"Krilaviciute","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0165","doi-asserted-by":"crossref","first-page":"E453","DOI":"10.5489\/cuaj.6341","article-title":"Utility of digital rectal examination in a population with prostate cancer treated with active surveillance","volume":"14","author":"Herrera-Caceres","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2026.06.009_b0170","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/pros.24203","article-title":"The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy","volume":"81","author":"Prebay","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2026.06.009_b0175","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JU.0000000000000617","article-title":"Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer","volume":"203","author":"Bjurlin","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.euros.2025.03.006","article-title":"Personalised prostate cancer diagnosis: evaluating biomarker-based approaches to reduce unnecessary magnetic resonance imaging and biopsy procedures","volume":"75","author":"Soeterik","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2026.06.009_b0185","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jama.2025.13722","article-title":"Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial","volume":"334","author":"Ng","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.06.009_b0190","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2026.06.009_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100563","article-title":"Evaluation of Artificial Intelligence-Based Gleason Grading Algorithms \u201cin the Wild\u201d","volume":"37","author":"Faryna","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2026.06.009_b0200","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(24)00220-1","article-title":"Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study","volume":"25","author":"Saha","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0205","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/his.15231","article-title":"Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage","volume":"85","author":"Nguyen","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2026.06.009_b0210","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0215","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","article-title":"Transperineal versus transrectal magnetic resonance imaging-targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial","volume":"86","author":"Hu","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0225","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(25)00100-7","article-title":"Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial","volume":"26","author":"Bryant","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0230","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(24)00912-7","article-title":"Prostate Cancer UK launches the TRANSFORM trial","volume":"403","author":"Burki","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.06.009_b0235","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/21681805.2021.1881612","article-title":"The G\u00d6TEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate","volume":"55","author":"Kohestani","year":"2021","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0240","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.2024.3841","article-title":"Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial","volume":"331","author":"Auvinen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2026.06.009_b0245","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.eururo.2023.09.027","article-title":"Multiparametric magnetic resonance imaging in prostate cancer screening at the age of 45 years: results from the first screening round of the PROBASE trial","volume":"85","author":"Boschheidgen","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0250","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.euf.2021.03.027","article-title":"Update from the ReIMAGINE prostate cancer screening study NCT04063566: inviting men for prostate cancer screening using magnetic resonance imaging","volume":"7","author":"Marsden","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.06.009_b0255","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.euo.2023.03.009","article-title":"An evaluation of screening pathways using a combination of magnetic resonance imaging and prostate-specific antigen: results from the IP1-PROSTAGRAM study","volume":"6","author":"Eldred-Evans","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0260","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.euf.2022.06.008","article-title":"Designing and implementing a population-based organised prostate cancer testing programme","volume":"8","author":"Alterbeck","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.06.009_b0265","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.euo.2023.12.005","article-title":"Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Matsukawa","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0270","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1200\/JCO.24.00152","article-title":"Stockholm3 in a multiethnic cohort for prostate cancer detection (SEPTA): a prospective multicentered trial","volume":"42","author":"Vigneswaran","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0275","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.eururo.2019.09.027","article-title":"Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study","volume":"77","author":"Zelic","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0280","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system. version 2.1; 2019 Update of Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0285","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.eururo.2018.05.035","article-title":"Prostate imaging-reporting and data system steering committee: PI-RADS v2 status update and future directions","volume":"75","author":"Padhani","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0290","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.juro.2012.07.024","article-title":"Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer","volume":"188","author":"Vargas","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0295","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40644-021-00414-6","article-title":"MRI-based radiomics models to assess prostate cancer, extracapsular extension and positive surgical margins","volume":"21","author":"He","year":"2021","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0300","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.euo.2025.01.009","article-title":"Active surveillance of grade Group 2 prostate cancer: oncological outcomes from a contemporary European cohort","volume":"8","author":"Baboudjian","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0305","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.euo.2022.03.007","article-title":"A multivariable approach using magnetic resonance imaging to avoid a protocol-based prostate biopsy in men on active surveillance for prostate cancer-data from the international multicenter prospective PRIAS study","volume":"5","author":"Luiting","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0310","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","article-title":"Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression","volume":"5","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0315","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.1016\/j.clgc.2020.05.008","article-title":"Active surveillance for intermediate-risk prostate cancer: systematic review and meta-analysis of current protocols and outcomes","volume":"18","author":"Enikeev","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2026.06.009_b0320","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.3390\/jcm12072732","article-title":"Comparison of outcomes of active surveillance in intermediate-risk versus low-risk localised prostate cancer patients: a systematic review and meta-analysis","volume":"12","author":"Mukherjee","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0335","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.eururo.2014.10.050","article-title":"Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review","volume":"67","author":"Schoots","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0340","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eururo.2016.01.026","article-title":"A critical analysis of the current knowledge of surgical anatomy of the prostate related to optimisation of cancer control and preservation of continence and erection in candidates for radical prostatectomy: an update","volume":"70","author":"Walz","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0345","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2015.07.037","article-title":"Nerve-sparing surgery technique, not the preservation of the neurovascular bundles, leads to improved long-term continence rates after radical prostatectomy","volume":"69","author":"Michl","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0350","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.juro.2017.12.037","article-title":"The effect of nerve sparing status on sexual and urinary function: 3-year results from the CEASAR study","volume":"199","author":"Avulova","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0355","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12957-024-03340-6","article-title":"Is there any difference in urinary continence between bilateral and unilateral nerve sparing during radical prostatectomy? A systematic review and meta-analysis","volume":"22","author":"Xiang","year":"2024","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0360","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/bco2.115","article-title":"Selection of patients for nerve sparing surgery in robot-assisted radical prostatectomy","volume":"3","author":"Vis","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.eururo.2026.06.009_b0365","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41391-020-00266-4","article-title":"Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer","volume":"24","author":"Preisser","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2026.06.009_b0370","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.euf.2021.05.009","article-title":"Evaluation of oncological outcomes and data quality in studies assessing nerve-sparing versus non-nerve-sparing radical prostatectomy in nonmetastatic prostate cancer: a systematic review","volume":"8","author":"Moris","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2026.06.009_b0375","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.06.009_b0380","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.eururo.2017.03.049","article-title":"Development and internal validation of a novel model to identify the candidates for extended pelvic lymph node dissection in prostate cancer","volume":"72","author":"Gandaglia","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0385","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","article-title":"A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0390","first-page":"970","article-title":"Evaluation of MSKCC Preprostatectomy nomogram in men who undergo MRI-targeted prostate biopsy prior to radical prostatectomy","volume":"37","author":"Glaser","year":"2019","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.eururo.2026.06.009_b0395","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/cancers15061683","volume":"15","author":"Di Pierro","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2026.06.009_b0400","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.euo.2023.05.003","volume":"6","author":"Gandaglia","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0405","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2021.05.006","article-title":"External validation and addition of prostate-specific membrane antigen positron emission tomography to the most frequently used nomograms for the prediction of pelvic lymph-node metastases: an international multicenter study","volume":"80","author":"Meijer","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0410","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.eururo.2025.04.017","article-title":"Updated prostate cancer risk groups by prostate-specific membrane antigen positron emission tomography prostate cancer molecular imaging standardized evaluation (PPP2): results from an international multicentre registry study","volume":"88","author":"Karpinski","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0415","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2016.01.012","article-title":"Decipher genomic classifier measured on prostate biopsy predicts metastasis risk","volume":"90","author":"Klein","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2026.06.009_b0420","article-title":"Validation of the combined clinical cell-cycle risk score to prognosticate early prostate cancer metastasis from biopsy specimens and comparison with other routinely used risk classifiers","volume":"8","author":"Hutten","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0425","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.urpr.2014.10.010","article-title":"The impact of a biopsy based 17-gene genomic prostate score on treatment recommendations in men with newly diagnosed clinically prostate cancer who are candidates for active surveillance","volume":"2","author":"Badani","year":"2015","journal-title":"Urol Pract"},{"key":"10.1016\/j.eururo.2026.06.009_b0445","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0450","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0455","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1200\/JCO.2006.09.2940","article-title":"Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies","volume":"25","author":"Lecouvet","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0460","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","article-title":"Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?","volume":"62","author":"Lecouvet","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0465","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bju.14374","article-title":"A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET\/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol","volume":"122","author":"Hofman","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.06.009_b0470","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","article-title":"Impact of (68)Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial","volume":"61","author":"Fendler","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0475","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00259-021-05296-1","article-title":"Prospective comparison of (18)F-PSMA-1007 PET\/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer","volume":"48","author":"Malaspina","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0480","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41585-022-00618-w","article-title":"The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer","volume":"19","author":"Wang","year":"2022","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0485","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.semnuclmed.2023.08.001","article-title":"A clinical role of PET-MRI in prostate cancer?","volume":"54","author":"Gammel","year":"2024","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0490","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","article-title":"PSMA ligands for PET imaging of prostate cancer","volume":"58","author":"Schwarzenboeck","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0495","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","article-title":"Focal unspecific bone uptake on [(18)F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging","volume":"48","author":"Gr\u00fcnig","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0500","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls","volume":"38","author":"Hofman","year":"2018","journal-title":"RadioGraphics"},{"key":"10.1016\/j.eururo.2026.06.009_b0505","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00259-021-05548-0","article-title":"Correction to: prospective intra\u2013individual blinded comparison of [(18)F]PSMA\u20111007 and [(68) Ga]Ga\u2011PSMA\u201111 PET\/CT imaging in patients with confirmed prostate cancer","volume":"49","author":"Pattison","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0510","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bju.14814","article-title":"Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team","volume":"124","author":"Murphy","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.06.009_b0515","article-title":"Artificial intelligence-based digital histologic classifier for prostate cancer risk stratification: independent blinded validation in patients treated with radical prostatectomy","volume":"9","author":"Fay","year":"2025","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.eururo.2026.06.009_b0520","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.euo.2023.03.010","volume":"6","author":"Vis","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0525","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0530","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, Part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0535","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2026.06.009_b0540","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.clon.2009.10.015","article-title":"A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence","volume":"22","author":"Beresford","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.eururo.2026.06.009_b0545","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0550","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2967\/jnumed.121.262821","article-title":"PSMA PET validates higher rates of metastatic disease for European Association of Urology biochemical recurrence risk groups: an international multicenter study","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0575","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","volume":"88","author":"Mazzone","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0580","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.euo.2024.09.015","article-title":"Prostate-specific membrane antigen positron emission tomography before reaching the phoenix criteria for biochemical recurrence of prostate cancer after radiotherapy: earlier detection of recurrences","volume":"8","author":"van Altena","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0585","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0590","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0595","doi-asserted-by":"crossref","unstructured":"G\u00fchne F, Radke S, Winkens T, et al. Differences in distribution and detection rate of the [(68)Ga]Ga-PSMA ligands PSMA-617. Pharmaceuticals (Basel) 2021;I&T and -11-Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer:15.","DOI":"10.3390\/ph15010009"},{"key":"10.1016\/j.eururo.2026.06.009_b0600","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1177\/02841851231184210","article-title":"Diagnostic performance of 18F-labeled PSMA PET\/CT in patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis","volume":"64","author":"Yang","year":"2023","journal-title":"Acta Radiol"},{"key":"10.1016\/j.eururo.2026.06.009_b0605","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A Phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (Osprey)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0610","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","article-title":"Comparison of (18)F-based PSMA radiotracers with [(68)Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer-a systematic review and meta-analysis","volume":"27","author":"Huang","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"68","key":"10.1016\/j.eururo.2026.06.009_b0615","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2022.05.010","article-title":"(18)F-PSMA-11 Versus. Ga-PSMA-11 positron emission tomography\/computed tomography for staging and biochemical recurrence of prostate cancer: a prospective double-blind randomised cross-over trial","volume":"82","author":"De Man","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0620","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1007\/s00259-025-07292-1","article-title":"PSMA PET\/CT in biochemical recurrence of prostate cancer with PSA levels\u2009\u2264\u2009.2\u00a0ng\/mL: a German multicenter analysis of conventional PSMA tracers, including [(68)Ga]Ga-PSMA-11, [(68)Ga]Ga-PSMA I&T, and [(18)F]PSMA-1007","volume":"52","author":"Burgard","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0625","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2214\/AJR.22.28665","article-title":"PI-RR: the prostate imaging for recurrence reporting system for MRI assessment of local prostate cancer recurrence after radiation therapy or radical prostatectomy-A review","volume":"220","author":"Abreu-Gomez","year":"2023","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.eururo.2026.06.009_b0630","first-page":"125","article-title":"Detection of local recurrence with 3-tesla MRI after radical prostatectomy: a useful method for radiation treatment planning?","volume":"32","author":"Buergy","year":"2018","journal-title":"In vivo"},{"key":"10.1016\/j.eururo.2026.06.009_b0635","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13014-015-0574-6","article-title":"Pelvic MRI findings in relapsed prostate cancer after radical prostatectomy","volume":"10","author":"Hernandez","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0640","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/0284186X.2016.1223342","article-title":"Proposal for magnetic resonance imaging-guided salvage radiotherapy for prostate cancer","volume":"56","author":"Dirix","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0645","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1148\/radiol.13122149","article-title":"Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?","volume":"268","author":"Donati","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2026.06.009_b0650","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jmri.26581","article-title":"Quantitative 3T multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after external-beam radiation therapy","volume":"50","author":"Dinis Fernandes","year":"2019","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0665","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline Part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0670","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1007\/s00259-025-07255-6","article-title":"Long-term outcomes of PSMA PET\/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis","volume":"52","author":"Di Giorgio","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0675","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2967\/jnumed.118.212563","article-title":"Outcome after PSMA PET\/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis","volume":"60","author":"Schmidt-Hegemann","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0680","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40644-023-00543-0","article-title":"Outcome of patients with biochemical recurrence of prostate cancer after PSMA PET\/CT-directed radiotherapy or surgery without systemic therapy","volume":"23","author":"Harsini","year":"2023","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0685","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00259-023-06185-5","article-title":"PSMA-PET\/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA <.2 ng\/ml","volume":"50","author":"Solomonidou","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0690","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2025.3746","article-title":"Prostate-specific membrane antigen PET-guided intensification of salvage radiotherapy after radical prostatectomy: a phase 2 randomized clinical trial","volume":"11","author":"Belliveau","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0695","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eururo.2024.01.012","article-title":"Impact of prostate-specific membrane antigen positron emission tomography\/computed tomography on prostate cancer salvage radiotherapy management: results from a prospective multicenter randomized Phase 3 trial (PSMA-SRT NCT03582774)","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0700","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00259-015-3202-7","article-title":"PET\/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data","volume":"43","author":"Fanti","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.eururo.2026.06.009_b0705","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00259-016-3329-1","article-title":"(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus. C-choline PET\/CT in prostate cancer relapse: results of a prospective trial","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0710","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline PET or PET\/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0715","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2967\/jnumed.120.256784","article-title":"Salvage radiotherapy management decisions in postprostatectomy patients with recurrent prostate cancer based on (18)F-Fluciclovine PET\/CT guidance","volume":"62","author":"Abiodun-Ojo","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0720","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","article-title":"Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis","volume":"43","author":"Shen","year":"2014","journal-title":"Skelet Radiol"},{"key":"10.1016\/j.eururo.2026.06.009_b0725","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1515\/cclm-2013-0675","article-title":"Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET\/CT in restaging prostate cancer patients: a meta-analysis","volume":"52","author":"Treglia","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0730","article-title":"The diagnostic role of (18)F-choline, (18)F-Fluciclovine and (18)F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109678","article-title":"Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study","volume":"184","author":"Scharl","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0740","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.06.009_b0745","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2025.12.003","article-title":"[18F]-fluciclovine or [68Ga]-PSMA-11 molecular imaging to guide dose escalation of salvage radiotherapy after radical prostatectomy for prostate cancer: the EMPIRE-2 trial","volume":"89","author":"Jani","year":"2026","journal-title":"Eur Urol"},{"issue":"Suppl. 3","key":"10.1016\/j.eururo.2026.06.009_b0750","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bju.16158","article-title":"The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy","volume":"133","author":"Roberts","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.06.009_b0755","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3390\/cancers14030781","article-title":"Value of targeted biopsies and combined PSMA PET\/CT and mp-MRI imaging in locally recurrent prostate cancer after primary radiotherapy","volume":"14","author":"Rasing","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2026.06.009_b0760","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00259-020-05025-0","article-title":"PET\/MRI in prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Evangelista","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0765","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40644-016-0099-8","article-title":"Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET\/CT and 3T multiparametric MRI without endorectal coil: a single center experience","volume":"16","author":"Cou\u00f1ago","year":"2016","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0770","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00259-017-3797-y","article-title":"Prospective head-to-head comparison of (11)C-choline-PET\/MR and (11)C-choline-PET\/CT for restaging of biochemical recurrent prostate cancer","volume":"44","author":"Eiber","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0775","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2967\/jnumed.118.225185","article-title":"The contribution of multiparametric pelvic and whole-body MRI to interpretation of (18)F-Fluoromethylcholine or (68)Ga-HBED-CC PSMA-11 PET\/CT in patients with biochemical failure after radical prostatectomy","volume":"60","author":"Metser","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0780","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s11307-019-01424-4","article-title":"Whole-body integrated [(68)Ga]PSMA-11-PET\/MR imaging in patients with recurrent prostate cancer: comparison with whole-body PET\/CT as the standard of reference","volume":"22","author":"Guberina","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.eururo.2026.06.009_b0785","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","article-title":"Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI","volume":"44","author":"Freitag","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0790","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"39","author":"Virgo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0805","doi-asserted-by":"crossref","unstructured":"Anttinen M, Ettala O, Malaspina S, et al. A prospective comparison of. Urol Oncol 2021; 4;18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography\/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Eur:635\u201344.","DOI":"10.1016\/j.euo.2020.06.012"},{"key":"10.1016\/j.eururo.2026.06.009_b0810","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2967\/jnumed.124.267751","article-title":"Composite prediction score to interpret bone focal uptake in hormone-sensitive prostate cancer patients imaged with [(18)F]PSMA-1007 PET\/CT","volume":"65","author":"Bauckneht","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0815","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0820","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0825","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic (68)Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0830","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2025.08.005","article-title":"SPARC: the standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: a Delphi analysis","volume":"89","author":"Herrmann","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.06.009_b0835","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.250702","article-title":"PSMA PET\/CT reporting: real-life inconsistencies, heterogeneity, and underutilization of scoring systems and interpretation frameworks","volume":"317","author":"Vargas","year":"2025","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2026.06.009_b0840","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2967\/jnumed.118.215434","article-title":"Unspecific (18)F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scanning, and MRI triple validation in patients with biochemical recurrence of prostate cancer","volume":"64","author":"Seifert","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0845","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00259-025-07331-x","article-title":"Assessing the frequency and accuracy of morphologic changes of focal bone lesions on [(68)Ga]Ga-PSMA-11 PET\/CT in prostate cancer","volume":"53","author":"Sivakumar","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0850","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2967\/jnumed.122.265077","article-title":"A VISION substudy of reader agreement on (68)Ga-PSMA-11 PET\/CT scan interpretation to determine patient eligibility for (177)Lu-PSMA-617 radioligand therapy","volume":"64","author":"Kuo","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0855","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2967\/jnumed.119.230318","article-title":"Total-body (68)Ga-PSMA-11 PET\/CT for bone metastasis detection in prostate cancer patients: potential impact on bone scan guidelines","volume":"61","author":"Pomykala","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0860","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [(177)Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0865","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1007\/s00330-025-11360-3","article-title":"Baseline PSMA PET\/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients","volume":"35","author":"Kleiburg","year":"2025","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2026.06.009_b0870","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","article-title":"Initial experience with volumetric (68)Ga-PSMA I&T PET\/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer","volume":"58","author":"Schmuck","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0875","doi-asserted-by":"crossref","first-page":"193","DOI":"10.62347\/NCJF9597","article-title":"Molecular tumor volume on PSMA PET\/CT is an independent imaging biomarker associated with progression-free survival in patients with oligorecurrent prostate cancer","volume":"15","author":"Cheng","year":"2025","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b0880","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/RLU.0000000000004763","article-title":"Tumor volume on PSMA PET as a prognostic biomarker in prostate cancer patients treated with cabazitaxel","volume":"48","author":"Shagera","year":"2023","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0885","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1200\/JCO.2022.40.16_suppl.5072","article-title":"Radiographic progression in the absence of prostate-specific antigen (PSA) progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of ARCHES","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0890","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.euo.2026.01.008","article-title":"Radiographic progression without prostate-specific antigen progression in metastatic hormone-sensitive prostate cancer: a retrospective analysis of the ENZAMET trial (ANZUP 1304)","volume":"9","author":"Inderjeeth","year":"2026","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0895","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.euo.2024.04.009","article-title":"Radiographic progression without corresponding prostate-specific antigen progression in patients with metastatic castration-sensitive prostate cancer receiving Apalutamide: secondary analysis of the Titan trial","volume":"8","author":"Fukuokaya","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0900","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0905","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.annonc.2025.12.007","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","volume":"37","author":"Turco","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0910","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO-25-02834","article-title":"Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4","volume":"44","author":"Armstrong","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0915","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1200\/JCO.2024.42.16_suppl.5070","article-title":"METRADS-P vs. RECIST\/PCWG criteria to detect disease progression in metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Tunariu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0920","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.eururo.2026.06.009_b0925","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bju.14876","article-title":"TheraP: a randomized phase 2 trial of 177 Lu- PSMA -617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)","volume":"124","author":"Hofman","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2026.06.009_b0930","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0935","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.06.009_b0940","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [(177)Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0945","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2308","article-title":"LBA65 efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH)","volume":"35","author":"Sartor","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0950","doi-asserted-by":"crossref","first-page":"S1627","DOI":"10.1016\/j.annonc.2025.09.101","article-title":"LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","volume":"36","author":"Tagawa","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0955","doi-asserted-by":"crossref","unstructured":"Kuo PH, Morris MJ, Hesterman J, et al. Quantitative. Radiology. GA: PHILIPPINE SUGAR MILLERS ASSOCIATION-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following (177)Lu-PSMA-617 (VISION Trial) 2024;68:312:e233460.","DOI":"10.1148\/radiol.233460"},{"key":"10.1016\/j.eururo.2026.06.009_b0960","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0965","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41391-025-01034-y","article-title":"Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"29","author":"Yanagisawa","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2026.06.009_b0970","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1470-2045(25)00339-0","article-title":"Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b0975","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0980","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/pros.21241","article-title":"High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer","volume":"71","author":"Minner","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2026.06.009_b0985","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b0990","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2026.06.009_b0995","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","article-title":"Radiation dosimetry in (177)Lu-PSMA-617 therapy using a single posttreatment SPECT\/CT scan: a novel methodology to generate time- and tissue-specific dose factors","volume":"61","author":"Jackson","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b1000","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2967\/jnumed.124.268325","article-title":"SPECT deserves RESPECT: the potential of SPECT\/CT to optimize patient outcomes with theranostics therapy","volume":"66","author":"Emmett","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b1005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2967\/jnumed.122.264398","article-title":"Evaluation of (177)Lu-PSMA-617 SPECT\/CT quantitation as a response biomarker within a prospective (177)Lu-PSMA-617 and NOX66 combination trial (LuPIN)","volume":"64","author":"Pathmanandavel","year":"2023","journal-title":"J Nucl Med"},{"issue":"177","key":"10.1016\/j.eururo.2026.06.009_b1010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2967\/jnumed.122.264677","article-title":"(177)Lu-PSMA SPECT quantitation at 6 weeks (Dose 2) predicts short progression-free survival for patients undergoing. Lu-PSMA-I&T therapy","volume":"64","author":"John","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b1015","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","article-title":"Early response monitoring during [(177)Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study","volume":"51","author":"Neubauer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2026.06.009_b1020","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2967\/jnumed.124.267955","article-title":"Impact of posttreatment SPECT\/CT on patient management during (177)Lu-PSMA-617 radiopharmaceutical therapy","volume":"65","author":"Yadav","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b1025","article-title":"Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT). Ther Adv","volume":"15","author":"Emmett","year":"2023","journal-title":"Med Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b1030","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2967\/jnumed.125.269640","article-title":"Prognostic value of posttherapy SPECT\/CT for overall survival in patients undergoing [(177)Lu]Lu-PSMA-617 radiopharmaceutical therapy: results from 3 clinical trials","volume":"66","author":"Kashyap","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2026.06.009_b1040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.06.009_b1045","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","volume":"36","author":"Tombal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b1050","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2026.02.009","article-title":"Final overall survival results from EORTC 1333\/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer","volume":"37","author":"Gillessen","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b1055","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b1060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1200\/JCO.2025.43.5_suppl.121","article-title":"Efficacy of 177 Lu-PSMA-617 with or without ARPIs for the treatment of mCRPC: VISION secondary analysis","volume":"43","author":"Yazdanpanah","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.06.009_b1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116131","article-title":"A roadmap for future clinical research in advanced prostate cancer: findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024","volume":"233","author":"Vogl","year":"2026","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2026.06.009_b1070","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.eururo.2025.01.003","article-title":"The co-IMPACT consortium: integrating prostate-specific membrane antigen positron emission tomography and radiotherapy in prostate cancer care","volume":"87","author":"Murthy","year":"2025","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382602230X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382602230X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:35:03Z","timestamp":1791837303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382602230X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":196,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S030228382602230X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.06.009","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}